Elvis Ruznic

Elvis Ruznic is a researcher in the Department of Radiotherapy and Radiation Oncology in Salzburg, Austria. His work focuses on lung cancer, particularly non-small cell lung cancer (NSCLC), and the intersection of radiation therapy with immunotherapy and computational modeling.

• Research Interests: Lung cancer, radiation therapy, immunotherapy, medical imaging, and artificial intelligence in oncology.
• Collaborations: Active contributor to the Austrian Radio-Oncological Lung Cancer Study Association (ALLSTAR) registry.

Key Contributions: Co-authored studies on durvalumab efficacy, dose escalation optimization, and AI-driven CT segmentation for NSCLC treatment. His work emphasizes improving survival outcomes and minimizing toxicity through multimodal therapies.

Scientific Awards: No awards explicitly listed in the provided data.